Impact of subsequent therapies in patients (pts) with advanced renal cell carcinoma (aRCC) receiving lenvatinib plus pembrolizumab (LEN+PEMBRO) or sunitinib (SUN) in the CLEAR study
暂无分享,去创建一个
R. Motzer | M. Voss | V. Grünwald | B. McGregor | T. Powles | R. Perini | F. Rolland | J. Goh | K. Mody | P. Maroto-Rey | D. Xing | C. Porta | J. McKenzie | J. Merchan